4th Asia-Pacifi c Abstracts to examine health and cost burden of HPV-related diseases to understand the potential impact of introducing HPV vaccine. OBJECTIVES: We aimed to evaluate the longterm health and cost burden associated with cervical cancer, cervical intraepitherial neoplasia (CIN) and genital warts from health-care provider perspective in Thailand.
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Covance Pty Ltd, North Ryde, NSW, Australia; 2 Covance Pty Ltd, North Ryde, NSW, Australia; 3 Gribbles Pathology, Clayton, VIC, Australia; 4 Genomic Health, Inc., Redwood City, CA, USA; 5 Genomic Health, Inc., Hong Kong, HKSAR, Hong Kong OBJECTIVES: Oncotype DX is a molecular diagnostic assay that measures quantitative expression of 21 genes within a breast tumor sample. The result is reported as a recurrence score (RS) that correlates with the risk of 10-year recurrence. The potential cost impact on chemotherapy treatment and an exploratory cost utility analysis were undertaken from the Australian health-care system perspective. METHODS: Input on the proportion of patients treated with chemotherapy and treatment regimens were obtained from an expert panel and a supplementary survey of Australian clinicians (oncologists and surgeons, n = 12). Data on the proportion of patients who would forgo chemotherapy based on knowledge of the RS and the incidence and cost of adverse events were obtained from published literature. RESULTS: The clinician input indicated that 33% of node negative and 84% of node positive women receive adjuvant chemotherapy on average. The most common treatments for node-negative patients were AC (anthracycline and cyclophosphamide) (77%) and FEC100 (fl uorouracil, epirubicin and cyclophosphamide) (16%) and for node-positive patients FEC-D (FEC plus docetaxel) (54%), AC + paclitaxel (26%) and TAC (docetaxel plus AC) (14%). Published switch rates away from chemotherapy are 20% for node negative and 24% for node positive patients. The cost saving due to a reduction in chemotherapy was estimated to be A$2264 per woman tested. After consideration for the cost of the assay (A$4200) and a published utility rate of 0.5, a A$/QALY gain was estimated at A$9986. CONCLUSIONS: Knowledge of the Oncotype DX RS has a cost-offset due to the reduction in chemotherapy and is likely to be cost-effective. These benefi ts refl ect the quality of life and survival benefi ts of a more targeted approach to treatment decision-making. Further analysis is warranted to include the potential costs of relapse avoided by use of the assay and any patient indirect costs in Australia.
PCN13 COST-BENEFIT ANALYSIS OF A 21-GENE RECURRENCE SCORE FOR EARLY STAGE BREAST CANCER IN SINGAPORE
de Lima Lopes G 1 , Chien R 2 , Hornberger J 3 1 Johns Hopkins Singapore International Medical Centre and Johns Hopkins University School of Medicine, Singapore; 2 Cedar Associates LLC, Menlo Park, CA, USA; 3 Cedar Associates LLC and Stanford University, Menlo Park, CA, USA BACKGROUND: Breast cancer represents a signifi cant burden of illness worldwide. Cost of cancer management is a key policy concern. The adoption of 21-gene breast cancer recurrence score (RS) was projected to be cost-effective. OBJECTIVES: To assess cost-benefi t of the 21-gene RS for lymph node negative, estrogen receptor positive early-stage breast cancer (ESBC) in Singapore from a patient's perspective. METHODS: We adopted a validated Markov model to calculate the cost implications of RS for an early-stage breast cancer patient. The probability of individual's risk of recurrence, chemotherapy benefi ts and decision impact of RS were derived from existing studies. The model accounted for both direct and indirect costs associated with adjuvant chemotherapy. Direct costs included chemotherapy drugs, supportive care drugs, administration, and management of adverse events adjusted by incidence, and cost of recurrence. Indirect costs included productivity loss during chemotherapy and distant recurrence. Chemotherapy regimen distribution and costs were obtained from medical oncologists at a private and a public cancer centers in Singapore. RESULTS: The pretest probabilities of risk of recurrence per woman as low, intermediate or high were 49.8%, 30.3%, and 19.9%, respectively. The average direct potential savings per patient tested in Singapore Dollars (SGD) for chemotherapy drug, supportive care, management of AE and administration were $2942, $1077, $169, and $1340, respectively. Per patient saving from productivity loss during treatment was $468. At manufacturer price, the model projects immediate realized savings of $430 with the adoption of the RS. The model also projects $1331 direct savings, and $2418 indirect savings from preventing distant recurrence. Multiple sensitivity analyses demonstrate the robustness of the savings with adoption of RS under a variety of conditions. CONCLUSIONS: For women with ESBC in Singapore, the RS is a cost-saving treatment decision tool.
PCN14 ADDITIONAL HEALTH AND ECONOMIC IMPACT OF THE BIVALENT VERSUS THE QUADRIVALENT HPV VACCINE IN TAIWAN: RESULTS OF A PREVALENCE-BASED MODEL
Ho T 1 , Van Enckevort PJ 2 , Demarteau N 3 1 GlaxoSmithKline, Taipei, Taiwan; 2 GlaxoSmithKline Biologicals, Singapore; 3 GlaxoSmithKline Biologicals, Wavre, Belgium OBJECTIVES: Two human papillomavirus (HPV) vaccines currently exist: a bivalent targeting oncogenic high-risk HPV-16/18 and a quadrivalent targeting high-risk HPV-16/18 and low-risk HPV-6/11. Based on data in their respective trials, the bivalent vaccine is likely to have higher effi cacy against non-vaccine oncogenic HPV-types (cross protection). The quadrivalent has an additional effect against genital warts. The differences in the annual impact of both vaccines on precancerous lesions, genital warts (GW) and cervical cancer (CC) were evaluated. METHODS: A static prevalencebased model was developed, which estimates the differences in lesions, GW, CC, and costs prevented between the two vaccines over a one-year period at steady state (i.e., when all women are vaccinated). The base case analysis was performed from a healthcare payer's perspective, including only National Health Insurance covered costs. In addition, an analysis from a societal perspective was performed, including also indirect costs and out-of-pocket payments. Epidemiological and cost data were obtained from published sources. Effi cacy fi gures were based on the latest results from each vaccine's respective clinical trial. Univariate sensitivity analyses were conducted, in which parameters were varied 20% up and down from the baseline value. RESULTS: Under this model, the bivalent vaccine would result in an additional reduction of 1486 ASCUS; 1768 CIN1; 1230 CIN2/3 and 166 CC cases per year, while the quadrivalent vaccine would result in an additional 7726 GW cases prevented per year. The additional annual costs averted with the bivalent vaccine was estimated at US$ 1.3 million and US$ 1.9 million from a health-care payer's and societal perspective, respectively. This outcome is most sensitive to cross protection fi gures. CONCLUSIONS: Vaccination with the bivalent vaccine is expected to have a higher impact than the quadrivalent vaccine on the prevention of precancerous lesions and CC in Taiwan, and would lead to more cost averted.
PCN15 COST ANALYSIS BETWEEN TYROSINE KINASE INHIBITOR VERSUS DOCETAXEL IN ADVANCED NON-SMALL CELL LUNG CANCER
Topibulpong N, Tanasanvimon S, Parinyanitikul N, Sriuranpong V Chulalongkorn University, Bangkok, Thailand OBJECTIVES: To determine the cost-effectiveness of the second line treatment of advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) comparing to docetaxel under health-care provider perspective. Only direct medical cost was considered. Outcomes included the patients' survivals. METHODS: We collected data of aNSCLC patients treated at the Medical Oncology Unit during the year 2009 in a prospective manner. Patients were followed until death. Direct medical costs included medicine cost, laboratory cost,
